JNJ-42041935 was the most potent inhibitor of PHD2181–417 with a pIC50 value of 7.0 ± 0.03. JNJ-42041935 caused a concentration-dependent elevation of cellular HIF-1α and erythropoietin release in Hep3B cells. JNJ-42041935 (100 μmol/kg, once a day for 14 days) was effective in reversing inflammation-induced anemia.
|Cell lines||Hep3B cells|
|Preparation method||The potency of compounds for stabilization of intracellular HIF-1α and release of erythropoietin into the media was assessed in the human hepatoma cell line Hep3B. Cells were cultured in Dulbecco's modified Eagle's medium/high glucose (Invitrogen) supplemented with 10% fetal calf serum and 2 mM l-glutamine, 1% nonessential amino acids, 1 mM sodium pyruvate, 50 IU/ml penicillin, and 50 μg/ml streptomycin. A range of concentrations was incubated in 96-well plates with 30,000 cells/well for 24 h. Incubation media were collected, and cells were subsequently lysed for assessment of cellular HIF-1α content and erythropoietin concentration.|
|Concentrations||1 to 10 μM|
|Incubation time||24 h|
|Animal models||Balb/C mice|
|Dosages||30, 100, and 300 μmol/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 30 mg/mL|
A role for prolyl hydroxylase domain proteins in hippocampal synaptic plasticity.
Corcoran A, et al. Hippocampus. 2013 Oct;23(10):861-72. PMID: 23674383.
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor.
Barrett TD, et al. Mol Pharmacol. 2011 Jun;79(6):910-20. PMID: 21372172.
|Related HIF Products|
PT2385 is an orally active, selective inhibitor of hypoxia inducible factor (HIF)-2alpha, with a Ki value of less than 50 nM.
Daprodustat (GSK1278863) is a novel, orally active HIF-prolyl hydroxylase inhibitor.
BIQ (FG-2216) is an orally available and potent inhibitor of prolyl-hydroxylase (PHD) with IC50 of 3.9 uM for PDH2 enzyme.
Oltipraz is a potent Nrf2 activator and a potent inducer of Phase II detoxification enzymes, most notably glutathione-S-transferase (GST). Phase 3.
|Molidustat (BAY 85-3934)
Molidustat (BAY 85-3934) is a potent hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with IC50 of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD, respectively. Phase 2.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.